| (e) Euan Ashley (50)
Non-Executive Director
(October 2020*)
Committee membership: Member of the
Science Committee.
Skills and experience:
Euan studied physiology and medicine at Glasgow
University, completing his junior doctor training at
Oxford University Hospitals NHS Trust, before
undertaking a DPhil in cardiovascular cellular biology
and molecular genetics at the University of Oxford.
In 2002, Euan moved to Stanford University in
California to train in cardiology and advanced heart
failure. At Stanford University, Euan’s research focuses
on genetic mechanisms of cardiovascular health and
disease. In addition to wet bench science, his laboratory
leverages artificial intelligence and digital health tools,
working with biotechnology and technology partners in
Silicon Valley, to advance both translational and clinical
research. Euan has received many awards including
recognition from the Obama White House for
contributions to personalised medicine and the
American Heart Association's Medal of Honor for
precision medicine.
Other appointments:
Euan is Associate Dean, Professor of Biomedical Data
Science and Professor of Cardiovascular Medicine
and Genetics at Stanford University in California.
(f) Michel Demaré (65)
Non-Executive Director
(September 2019*)
Committee membership: Chair of the Remuneration
Committee and member of the Audit Committee
and the Nomination and Governance Committee.
Skills and experience:
Michel was previously Vice-Chairman of UBS Group AG
(2010 to 2019), Chairman of Syngenta and the Syngenta
Foundation for Sustainable Agriculture (2013 to 2017)
and Chairman of SwissHoldings (2013 to 2015).
Between 2005 and 2013, Michel was CFO of ABB Ltd
and also acting interim CEO during 2008. He joined
ABB from Baxter International Inc., where he was CFO
Europe from 2002 to 2005. Prior to that, he spent 18
years at The Dow Chemical Company, in several
international finance functions, including the CFO of
Dow’s Global Polyolefins and Elastomers division
between 1997 and 2002. He began his career as a
banking officer at Continental Illinois’ Belgian subsidiary.
Michel graduated with an MBA from the Katholieke
Universiteit Leuven, Belgium, and holds a degree in
applied economics from the Université Catholique de
Louvain, Belgium.
Other appointments:
Michel is a Non-Executive Director of Vodafone Group
Plc and Louis Dreyfus Int’l Holdings BV, Chairman of
IMD Business School and Chairman of Nomoko AG.
(g) Deborah DiSanzo (62)
Non-Executive Director
(December 2017*)
Committee membership: Member of the Audit
Committee.
Skills and experience:
Deborah is President of Best Buy Health for Best
Buy Co. Inc. Best Buy Health provides digital health
solutions in active aging, virtual care, and consumer
health. Her oversight of Best Buy Health includes
GreatCall, a leading provider of connected health and
personal emergency response services to the aging
population, which Best Buy acquired in 2018. She
also leads the incubation, strategy and corporate
development teams focused on scaling health initiatives
at Best Buy. Deborah holds an appointment at the
Harvard TH Chan School of Public Health teaching
Artificial Intelligence in Health. Until December 2018,
she served as General Manager of IBM Watson Health.
Prior to IBM, until 2014, Deborah held multiple senior
executive positions at Philips Healthcare where she
also served as Chief Executive Officer. She has
also held various management roles at Agilent and
Hewlett-Packard. Deborah has been honoured by
multiple organisations as a top health influencer. She
holds an MBA from Babson College and is a Harvard
University Advanced Leadership Initiative 2019 Fellow.
Other appointments:
Deborah is President of Best Buy Health for Best Buy
Co. Inc.
(h) Diana Layfield (51)
Non-Executive Director
(November 2020*)
Committee membership: Member of the Science
Committee.
Skills and experience:
Diana has broad global business experience which
began in the pharmaceutical and biotech sector. She
has held senior leadership roles in the technology sector
and international banking, including senior positions
at Standard Chartered Bank, as the CEO of a start-up
technology company, and in Healthcare and Life
Sciences at McKinsey & Co.. Until December 2020,
Diana was a Non-Executive Director and a member
of the Audit, Ethics and Corporate Responsibility, and
Nomination Committees of Aggreko plc. Diana has
a BA from Oxford University and an MA in Public
Administration and International Economics from
Harvard University.
Other appointments:
Diana is President, EMEA Partnerships at Google,
driving technology transformation and is also
Vice-President, ‘Next Billion Users’ & Product
Management, leading the development of products
and services for future Google users, and is also a
Council Member of the London School of Hygiene &
Tropical Medicine. Diana is Chair and Board member
of CDC Group PLC.
(i) Sheri McCoy (63)
Non-Executive Director
(October 2017*)
Committee membership: Member of the Audit
Committee, the Remuneration Committee and
the Sustainability Committee.
Skills and experience:
Until February 2018, Sheri was Chief Executive Officer
and a Director of Avon Products, Inc. Prior to joining
them in 2012, she had a distinguished 30-year career at
Johnson & Johnson, latterly serving as Vice Chairman
of the Executive Committee, responsible for the
Pharmaceuticals and Consumer business segments.
Sheri joined Johnson & Johnson as an R&D scientist
and subsequently managed businesses in every major
product sector, holding positions including Worldwide
Chairman, Surgical Care Group and Division President,
Consumer. She holds a Bachelor of Science degree in
textile chemistry from the University of Massachusetts
Dartmouth, a Master’s degree in chemical engineering
from Princeton University and an MBA from Rutgers
University, both in New Jersey, US.
Other appointments:
Sheri serves on the boards of Stryker, Kimberly-Clark
Novocure and Laronde. She is also an industrial adviser
for EQT, in connection with which she serves on the
boards of Galderma and Parexel.
(j) Tony Mok (61)
Non-Executive Director
(January 2019*)
Committee membership: Member of the Science
Committee.
Skills and experience:
Tony is the Li Shu Fan Medical Foundation endowed
Professor and Chairman of the Department of Clinical
Oncology at the Chinese University of Hong Kong.
His work includes multiple aspects of lung cancer
research, with his main focus on biomarker and
molecular targeted therapy in lung cancer. He has
led and co-led multiple international Phase III trials,
including as the principal investigator and first author on
the landmark Iressa Pan-Asia Study, which confirmed
the application of precision medicine for advanced lung
cancer. He has also contributed to the development of
clinical research infrastructure in China and Asia. Tony
is the Past President of International Association for the
Study of Lung Cancer, and currently on the Board of
Directors of the American Society of Clinical Oncology.
His work has been recognised by numerous awards
including the ESMO Lifetime Achievement Award in
2018 and Giant of Cancer Care in 2020.
Other appointments:
Tony is a Non-Executive Director of Hutchison China
MediTech Limited (Chair of Nomination Committee) and
a co-founder and the Chairman of Sanomics Limited
(merged with ACT Genomic Limited since 2021).
7 Notice of Annual General Meeting 2022 and Shareholders’ Circular
Notice of Annual General Meeting 2022
and Shareholders’ Circular continued |